Vanguard Group
ANTX icon

Vanguard Group’s AN2 Therapeutics ANTX Stock Holding History

Vanguard Group’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$1.23M Hold
1,080,070
– – ﹤0.01% 3715
2025
Q3 		$1.37M Buy
1,080,070
+44,123
+4% +$50.4K ﹤0.01% 3693
2025
Q2 		$1.1M Hold
1,035,947
– – ﹤0.01% 3719
2025
Q1 		$1.41M Hold
1,035,947
– – ﹤0.01% 3599
2024
Q4 		$1.43M Sell
1,035,947
-5,580
-0.5% -$6.77K ﹤0.01% 3657
2024
Q3 		$1.11M Hold
1,041,527
– – ﹤0.01% 3735
2024
Q2 		$2.24M Sell
1,041,527
-6,242
-0.6% -$14.9K ﹤0.01% 3522
2024
Q1 		$3.41M Sell
1,047,769
-4,822
-0.5% -$52.5K ﹤0.01% 3432
2023
Q4 		$21.6M Buy
1,052,591
+112,700
+12% +$1.89M ﹤0.01% 2561
2023
Q3 		$15.1M Buy
939,891
+387,092
+70% +$4.38M ﹤0.01% 2670
2023
Q2 		$4.7M Sell
552,799
-49,126
-8% -$353K ﹤0.01% 3334
2023
Q1 		$5.94M Buy
601,925
+12,525
+2% +$139K ﹤0.01% 3220
2022
Q4 		$5.62M Buy
589,400
+404,946
+220% +$5.42M ﹤0.01% 3249
2022
Q3 		$3.21M Buy
184,454
+2,063
+1% +$24K ﹤0.01% 3547
2022
Q2 		$1.41M Buy
182,391
+107,658
+144% +$1.43M ﹤0.01% 3966
2022
Q1 		$1.13M Buy
+74,733
New +$1.13M ﹤0.01% 4168

Other funds holding ANTX

AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return
Bank of Nova Scotia
Bank of Nova Scotia Toronto, Ontario, Canada $57.2B AUM 35.3% 1-Year Est. Return
LCM
Landscape Capital Management Englewood, New Jersey $1.58B AUM 26.88% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group's ANTX Position: Q4 2025 in Review

Vanguard Group held its AN2 Therapeutics (ANTX) position steady in Q4 2025 at 1,080,070 shares worth $1.23M. The position accounts for ﹤0.01% of the portfolio, ranked #3715.

Vanguard Group first reported a position in ANTX in Q1 2022 and has held it in 16 quarters since. The position peaked at $21.6M in Q4 2023. 37 funds tracked by Wall St. Rank hold ANTX as of Q4 2025.

  • Vanguard Group held 1,080,070 shares of AN2 Therapeutics worth $1.23M as of Q4 2025.
  • Vanguard Group left its AN2 Therapeutics share count unchanged in Q4 2025.
  • AN2 Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3715 holding.
  • Vanguard Group first reported a position in AN2 Therapeutics in Q1 2022 and has held it in 16 quarters since.
  • Vanguard Group's AN2 Therapeutics position peaked at $21.6M in Q4 2023.
  • 37 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.